Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb:32:100744.
doi: 10.1016/j.eclinm.2021.100744. Epub 2021 Feb 4.

Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?

Affiliations

Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?

Céleo Ramírez et al. EClinicalMedicine. 2021 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

References

    1. Harrington D.P., Baden L.R., Hogan J.W. A Large, simple trial leading to complex questions. N Engl J Med. 2020 doi: 10.1056/NEJMe2034294. - DOI - PMC - PubMed
    1. Johns Hopkins University, Medicine. COVID Resource Center. (Online). https://coronavirus.jhu.edu/map.html (Reviewed01/10/2021).
    1. Swissinfo.ch. [Recomiendan uso de Ivermectina para combatir la covid-19 en Honduras]. (Online). https://www.swissinfo.ch/spa/coronavirus-honduras_recomiendan-uso-de-ive... (Reviewed01/10/2021).
    1. Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178 - PMC - PubMed
    1. Chaccour C., Casellas A., Blanco-Di Matteo A. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021 doi: 10.1016/j.eclinm.2020.100720. - DOI - PMC - PubMed

LinkOut - more resources